A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of PA9159 Inhalation Aerosol in Healthy Adult Subjects in China
Latest Information Update: 14 Apr 2025
At a glance
- Drugs PA 9159 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Anhui Palo Alto Pharmaceuticals
- 14 Apr 2025 New trial record